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TIP as consolidation chemotherapy achieved durable CR. 
Five additional patients were given further chemother-
apy and achieved durable CR. Grade 4 leukocytopenia 
and thrombocytopenia were observed in 91 and 42 % of 
patients, respectively; all were managed with routine sup-
portive care. Grade 2 and grade 3 sensory neuropathy was 
observed in 37 and 2 % of patients, respectively.
Conclusions The TIP was effective for relapsed patients 
with favorable risk features and selected CDDP-refractory 
GCT patients. Results of TIP as consolidation for patients 
with unfavorable response to the initial chemotherapy were 
also encouraging. The toxicities were mainly myelosup-
pression and sensory neuropathy.
Keywords TIP · Salvage · Chemotherapy · Germ cell 
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Introduction
About 80 % of patients with advanced germ cell tumor 
(GCT) can currently be cured with cisplatin-based chem-
otherapy and surgery, but patients who relapse after ini-
tial treatment or patients who did not respond completely 
to chemotherapy have a poor prognosis. One possible 
approach to improve outcome is high-dose chemotherapy 
(HDCT) with autologous stem-cell rescue (Einhorn et al. 
2007; Kondagunta et al. 2007). Although large retrospec-
tive analysis suggests a benefit from HDCT as the first sal-
vage chemotherapy (Lorch et al. 2011), the treatment is not 
feasible for all patients. Another approach is risk-adapted 
management in a salvage setting.
The Memorial Sloan-Kettering Cancer Center (MSKCCC) 
group proposed the following favorable prognostic factors 
for achieving a complete response (CR) to cisplatin plus 
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Purpose The purpose of the study was to assess the 
efficacy of TIP as salvage chemotherapy for germ cell 
tumor (GCT) patients with relapsed disease or cisplatin 
(CDDP)-refractory disease and consolidation chemother-
apy for patients who responded unfavorably to first-line 
chemotherapy.
Methods Forty-three patients with advanced GCT were 
treated with TIP. Eleven with relapsed disease and five with 
CDDP-refractory disease received TIP as salvage chemo-
therapy. The remaining 27 received TIP as consolidation 
chemotherapy following initial induction chemotherapy. 
All patients received prophylactic granulocyte colony-stim-
ulating factor.
Results In total, 116 cycles of TIP were administered with 
a median of three cycles (range 1–4 cycles) per patient. 
Before TIP, 33 patients showed elevated tumor marker and 
23 patients (70 %) achieved marker normalization with the 
chemotherapy. One of six (17 %) patients with refractory 
disease and 5 of 10 (50 %) patients with relapsed disease 
achieved durable complete response (CR) after TIP with or 
without surgery. Eighteen of 27 (67 %) patients receiving 
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ifosfamide conventional-dose salvage therapy: (1) testicu-
lar GCT, (2) prior treatment limited to one program or six or 
fewer cycles of cisplatin, and (3) progression after either a CR 
or a partial response (PR) with normal serum tumor markers 
(McCaffrey et al. 1997). Motzer et al. conducted a prospec-
tive study with a combination of paclitaxel, ifosfamide, and 
cisplatin (TIP) as salvage therapy for relapsed patients having 
those favorable risk features (Motzer et al. 2000). The results 
were promising: the response rate was 80 %, and progres-
sion-free survival was up to 73 % with a median follow-up of 
33 months (Motzer et al. 2000). The results were confirmed 
in a subsequent MSKCC study treating 46 patients with the 
same regimen (Kondagunta et al. 2005).
Because TIP is less toxic than HDCT, several investiga-
tors studied TIP for patients having unfavorable risk factors 
including refractory disease or more intense prior chemo-
therapy (Mardiak et al. 2005; Mead et al. 2005). Although 
overall results were somewhat inferior compared to the 
MKSCC series, Park et al. reported TIP achieved durable 
CR, even in some patients with absolutely (CDDP)-refrac-
tory disease (Park et al. 2011). However, at present, data on 
the efficacy of TIP beyond its original indication are limited.
In 2003, we reported preliminary results on TIP for eight 
patients with advanced GCT (Kawai et al. 2003). The pur-
pose of the study was to test the feasibility of TIP for Japa-
nese patients in a salvage setting and also to the efficacy of 
TIP as consolidation chemotherapy for patients who had 
responded unfavorably to first-line chemotherapy. Although 
only three patients were treated for the latter indication, all 
patients having extra-pulmonary visceral metastases achieved 
durable CR. The treatment was better tolerated when com-
pared with our experience of HDCT (Miyazaki et al. 2000) 
or that of Japanese multicenter study (Miki et al. 2007) for the 
same indication. Because the results were promising, we have 
been used TIP not only as salvage but also as consolidation 
chemotherapy. We retrospectively analyzed and here report 
the results of 43 patients treated with TIP.
Patients and methods
Patients
Forty-three male patients with advanced GCT were treated 
with TIP at Tsukuba University Hospital between 2000 and 
2012. The median age at the treatment was 31 years (range 
20–54 years). Forty-one patients had primary testicular 
tumors, and two patients were diagnosed with extrago-
nadal GCT originating in the retroperitoneum; 40 patients 
had non-seminoma, and three patients had seminoma. All 
patients but one had histologically confirmed GCT with 
measurable disease and elevated serum tumor markers. The 
remaining patient had a burned-out tumor in the right testis, 
retroperitoneal lymph node, and lung metastases. He was 
diagnosed with non-seminoma based on the tumor marker 
profile. Pretreatment evaluation included a history and 
physical examination, chest X-ray, serum tumor markers, 
and routine blood chemistries. Depending on the sites of 
metastatic disease, all patients underwent computed tomog-
raphy of the chest and abdomen and/or pelvis.
Initially, paclitaxel, the key drug of the regimen, has not 
been approved for GCT by the Japanese Ministry of Health, 
Labor and Welfare (MHLW). Therefore, the use of pacli-
taxel for patients with GCTs was reviewed and approved by 
the Committee of the Tsukuba University Hospital Investi-
gative Fund. Subsequently, TIP was registered as salvage 
chemotherapy regimen for metastatic germ cell cancer by 
the Cancer Board of the Tsukuba University Hospital. The 
written informed consent for TIP was obtained from each 
patient. In Japan, paclitaxel was approved for refractory or 
relapsed germ cell cancer by NHLW since 2012.
Treatment program
The TIP consisted of paclitaxel 175 mg/m2 by 24-h infusion 
on day 1, followed by ifosfamide 1.2 g/m2 infusion over 
2 h and cisplatin 20 mg/m2 given over 2 h on days 2–6. The 
dosages and schedule for cisplatin and ifosfamide adminis-
tration were identical to the TIP regimen reported by Motzer 
et al. (Motzer et al. 2000), but the dose of paclitaxel was 
fixed at 175 mg/m2 in the present study. Mesna 240 mg/m2 
was administered intravenously before ifosfamide infusions 
and every 4 h thereafter for a total of three doses per day. All 
patients received prophylactic premedication with 20 mg 
dexamethasone 12 and 6 h before paclitaxel and intravenous 
ranitidine and oral diphenhydramine (each 50 mg) 30 min 
prior to paclitaxel administrations. Standard anti-emetic 
and hydration protocols were followed. Patients received 
prophylactic subcutaneous injection of granulocyte colony-
stimulating factor (G-CSF) daily from day 7. If the WBC 
count exceeded 10,000/µl, G-CSF therapy was discontin-
ued. Courses were repeated every 21 days. The subsequent 
cycle was withheld until the granulocyte count was >500/µl 
and the thrombocyte count was >75,000/µl.
For salvage therapy, four cycles of TIP were given to 
patients with relapsed and CDDP-refractory disease. When 
used as consolidation chemotherapy, TIP was subsequently 
started after initial induction chemotherapy. In principle, our 
induction chemotherapy program was three courses of bleo-
mycin, etoposide, and cisplatin (BEP) (Williams et al. 1987) 
for good-prognosis patients and four courses of BEP for 
intermediate- and poor-prognosis patients. For patients hav-
ing risk factors for bleomycin pulmonary toxicity, etoposide 
and cisplatin (EP) or etoposide, ifosfamide, and cisplatin 
(VIP) (Nichols et al. 1998) were used as alternative induc-
tion chemotherapy. When response to the initial induction 
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chemotherapy was unfavorable, TIP was started with the 
subsequent treatment cycle and repeated until tumor marker 
normalization. If toxicities were acceptable, one more cycle 
of TIP was administrated after tumor maker normaliza-
tion. In both settings, if tumor maker normalization was not 
achieved by four cycles of TIP, the treatment was changed 
to another chemotherapy or marker-positive surgery.
Evaluation of response and toxicities
Clinical response was evaluated according to the criteria in 
the General Rules for Clinical and Pathological Studies on 
Testicular Tumors of the Japanese Urological Association. 
CR was defined as the disappearance of all evidence of dis-
ease when documented by imaging and all tumor marker 
levels. PR with tumor marker-negative findings (PRm−) 
was defined as a ≥50 % reduction in the product of perpen-
dicular diameters for each indicator lesion and normaliza-
tion of previously elevated tumor marker levels. PR with 
tumor marker-positive findings (PRm+) was defined as 
a ≥50 % reduction in the product of perpendicular diam-
eters for each indicator lesion, but without complete nor-
malization of tumor marker levels. Patients showing PR to 
chemotherapy and complete surgical resection of fibrosis, 
necrosis, and mature teratoma were considered to have 
complete pathological remission. Progressive disease (PD) 
was defined as a 25 % increase in the product of perpen-
dicular diameters for any lesion or the appearance of any 
new lesions. No change (NC) was defined as disease that 
did not meet any of the above criteria, irrespective of tumor 
marker normalization.
Survival duration was measured from the date of the 
initiation of TIP to the last follow-up appointment or until 
death. Evaluation of toxicities was classified according to 
the National Cancer Institute Common Toxicity Criteria for 
Adverse Events, version 4.0 (CTCAE v4.0).
Statistical analysis
Survival curves were constructed by the Kaplan–Meier 
method and compared using the log-rank test. In both anal-
yses, the level of significance was set at P < 0.05. Statisti-
cal analysis was performed using Jmp®10 software (SAS 
Institute Inc., Cary, NC).
Results
Patient characteristics
The patients’ backgrounds are summarized in Table 1. Six-
teen patients received TIP as salvage chemotherapy. Of 
them, ten patients were relapsed cases who suffered disease 
progression after CR to prior chemotherapy and/or surgery. 
Six patients were considered to have CDDP-refractory 
disease because tumor progression occurred during prior 
CDDP-based chemotherapy or within four weeks of the 
last CDDP-based chemotherapy. As salvage chemotherapy, 
11 of 16 patients received TIP as second-line chemother-
apy, whereas the other five patients received the treatment 
as third-line or later chemotherapy.
The remaining 27 patients received TIP as consolida-
tion chemotherapy. At the start of the initial chemotherapy, 
three patients (11 %) were classified as having a good prog-
nosis, four patients (15 %) as intermediate prognosis, and 
20 patients (74 %) as poor prognosis according to the clas-
sification defined by the International Germ Cell Cancer 
Collaborative Group (IGCCCG) (International Prognostic 
Factor Study Group 1997). The initial chemotherapy was 
BEP for 20 patients, VIP for two patients, VIP/BEP for 
two patients, and EP/BEP for three patients. In principle, 
TIP was introduced when responses to the initial induc-
tion chemotherapy were unsatisfactory. Twenty patients 
(74 %) were marker-positive at the start of TIP, 18 were 
Table 1  Patient characteristics
No. %







Not known 1 2
Sites of disease














No. of prior regimens for relapsed/refractory cases 16
Third line or more 2 13
Second line 3 19
Induction 11 69
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hCG-positive, and 8 were AFP-positive. The remain-
ing seven patients with normalized tumor markers had 
unrespectable residual tumors at the start of TIP. TIP was 
started after four courses of initial chemotherapy for 10 
patients and after three courses for 17 patients. In the latter 
cases, the up-front TIP introduction was selected because 
marker decline during the three initial courses lead us to 
expect that one additional course of initial chemotherapy 
would fail to achieve marker normalization.
Treatment and toxicity
In total, 116 cycles of TIP were administered with a median 
of three cycles per patient (range 1–4 cycles). The median 
number of days between cycles was 21 days (range 21–
65 days). The reasons for delays were leukocytopenia in 10 
cycles, thrombocytopenia in 15 cycles, allergic reaction to 
transfusion in two cycles, or radiological examinations or 
others in seven cycles.
The toxicity profile is shown in Table 2. The toxicity of 
TIP was considered tolerable except in one patient. This 
patient developed grade 3 sensory neuropathy at the first 
course of TIP and refused further treatment. Otherwise, 16 
patients developed grade 1 or grade 2 sensory neuropathy. 
Myelosuppression was the major toxicity. Most patients 
developed grade 3 or grade 4 leukocytopenia despite rou-
tine prophylactic use of G-CSF. Among them, 23 (53 %) 
patients developed neutropenic fever, but all of whom were 
successfully treated with empirical broad-spectrum antibi-
otics. Red blood cell and platelet transfusion were needed 
for 29 patients (67 %) and 21 patients (49 %), respectively.
Response and survival
Response was assessed in all patients as shown in Table 3. 
Before TIP, 33 patients showed elevated tumor marker, of 
them 23 patients (70 %) achieved marker normalization 
with the chemotherapy. In total, 24 patients (56 %) achieved 
CR: 6 patients with CR after chemotherapy alone and 18 
patients with adjunctive surgery for residual tumor after 
chemotherapy. In the latter cases, pathological examination 
revealed necrosis or teratoma in 15 patients and viable germ 
cell cancer in three patients. The CR rate of patients receiv-
ing TIP as consolidation chemotherapy was 67 %, which 
was higher than that of refractory cases (17 %) or relapsed 
cases (50 %). However, it is notable that the high CR rate 
was the effect of combined induction chemotherapy and 
TIP. There were eight patients (19 %) with PR with tumor 
marker-negative findings (PRm−) and four patients (9 %) 
with PR with tumor marker-positive findings (PRm+). 
The remaining five patients (12 %) and two patients (5 %) 
exhibited NC and PD, respectively. Seventeen of 19 non-CR 
patients received further chemotherapy after TIP.
As a result, 31 of the 43 patients achieved durable dis-
ease-free status. All 31 patients are currently alive with-
out evidence of disease at a median follow-up duration of 
58 months (range 19–166 months). As shown in Fig. 1a, 
the 5-year overall survival (OS) rates of refractory and 
relapsed cases were 33 and 66 %, respectively. Figure 1b 
represented the OS of patients who received TIP as con-
solidation chemotherapy according to the IGCCCG classi-
fication. The OS rates of patients with good- or intermedi-
ate-prognosis disease were 100 %. The 5-year OS rate of 
patients with poor-prognosis disease was 78 %.
Table 2  Toxicity (CTCAE v4.0)
All grade Grade 3 Grade 4
n (%) n (%) n (%)
Hematological
Leukocytopenia 43 (100) 3 (7) 39 (91)
Thrombocytopenia 42 (98) 14 (33) 18 (42)
Anemia 43 (100) 30 (70) 4 (9)
Febrile neutropenia 23 (53) 23 (53) 0
Non-hematological
Nausea or vomiting 23 (53) 4(9) 0
Neuropathy (sensory) 17 (40) 1 (2) 0
Myalgia/arthralgia 11 (26) 0 0
Acoustic nerve disorder 2 (5) 0 0
AST/ALT 4 (9) 0 0
Dysgeusia 1 (2) 0 0
Table 3  TIP therapy results
CR complete response, 
PRm− partial response with 
normalized markers, PRm+ 
partial response without 
normalized markers, NC no 
change, PD progressive disease
n (%) n (%) n (%)
Refractory Relapse Consolidation
Total 6 (100) 10 (100) 27 (100)
CR to chemotherapy ± resection of necrosis/teratoma 1 (17) 4 (40) 16 (59)
CR to chemotherapy + resection of viable germ cell tumor 0 1 (10) 2 (7)
PRm− 2 (33) 1 (10) 5 (19)
PR 171+ 1 (17) 2 (20) 1 (4)
NC 2 (33) 2 (20) 1 (4)
PD 0 0 2 (7)
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Discussion
The TIP was originally developed as first-line salvage 
chemotherapy for testicular germ cell cancer patients who 
relapsed after good response (CR or PRm−) to prior chem-
otherapy (Motzer et al. 2000; Kondagunta et al. 2005). TIP 
has become one of the most widely accepted conventional-
dose salvage chemotherapy in Japan. Recently, Japanese 
GCT guideline recommended TIP as salvage chemotherapy 
along with vinblastine, ifosfamide, and cisplatin (VeIP)/
VIP. In the present study, we evaluated the activity of TIP 
for GCT patients in three situations: salvage setting for 
relapsed cases, salvage setting for CDDP-refractory cases, 
and the consolidation setting as consolidation chemother-
apy. The conditions of the latter two categories are different 
from original indication for TIP.
In this series, 5 of 10 patients (50 %) with relapsed 
disease achieved a durable CR after TIP. One additional 
patient was salvaged with a combination of gemcitabine 
and oxaliplatin (GEMOX) (Kollmannsberger et al. 2004) 
after TIP. Consequently, the 5-year OS was 66 %. The 
durable CR rate was lower than TIP series from MKSCC, 
but our series includes two patients treated in either a third- 
or fourth-line setting. One additional patient underwent 
biopsy of non-responding lymph node metastasis after one 
cycle of TIP. The pathological diagnosis was primitive neu-
roectodermal tumor (PNET). Those three patients died of 
germ cell cancer or PNET. When limited to the remaining 
seven patients having favorable risk features as defined by 
MKSCC, the durable CR rate after TIP was 71 %, which 
was identical to the results of the MKSCC series (Motzer 
et al. 2000; Kondagunta et al. 2005).
In contrast to relapsed cases, there has been limited 
information on the efficacy of TIP against CDDP-refractory 
disease. We treated six patients in this category. It is nota-
ble that those patients had other multiple unfavorable 
risk features including either third- or fourth-line setting 
(three patients) or progression during prior chemotherapy 
(four patients). Despite this, two of six patients (33 %) 
responded to TIP; one patient had CR after TIP and sur-
gery and another patient had PRm- after one cycle of TIP. 
Despite the favorable initial response in the latter case, we 
were forced to change TIP to GEMOX due to the devel-
opment of grade 2 hearing impairment. Because both 
patients achieved long-term CR, the 5-year OS of patients 
with CDDP-refractory disease was 33 %. Although patient 
number of the present study is limited, recently, Park et al. 
reported the similar efficacy of TIP against relapsed or 
refractory patients having unfavorable risk features (Park 
et al. 2011). They reported that 3 of 7 patients (43 %) with 
CDDP-refractory disease achieved durable CR. These 
findings might suggest the applicability of TIP for some 
patients with CDDP-refractory disease. At present, little is 
known about which subset of patients with CDDP-refrac-
tory disease can derive a benefit from TIP. From this point 
of view, it is notable that two responding patients in our 
series had responded well (both PRm−) to the last chemo-
therapy before introduction of TIP, but the results should be 
interpreted with caution and further studies are needed.
In addition to salvage setting, we tested the efficacy of 
TIP as consolidation for patients who had shown an unfa-
vorable response to the initial induction chemotherapy. Of 
them, all seven patients with good- or intermediate-prog-
nosis disease and 11 of 20 (55 %) of patients with poor-
prognosis disease achieved durable CR after TIP with or 
without surgery. Eight of nine non-CR patients were fur-
ther treated with third-line or more chemotherapy and/or 
surgery, five patients ultimately achieved durable CR, and 
Fig. 1  a Overall survival rate of patients receiving TIP as salvage chemotherapy for relapsed disease or CDDP-refractory disease, and b overall 
survival rate of patients receiving TIP as consolidation chemotherapy after initial induction chemotherapy according to IGCCCG
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three patients died of cancer. The remaining patient with 
PRm− status underwent RPLND after TIP, but the resec-
tion was incomplete. The patient died of progressive tera-
toma with malignant transformation. Consequently, the 
5-year OS rate of patients with poor-prognosis disease was 
78 %. It must be emphasized that the high OS rate results 
from initial chemotherapy, TIP or other chemotherapy regi-
mens in some cases, but the favorable outcomes presented 
here suggest the benefit of TIP as consolidation chemo-
therapy. Although a different strategy, several investiga-
tors recently tested the efficacy of including paclitaxel in 
induction chemotherapy. A randomized study comparing 
four courses of BEP and paclitaxel-BEP (T-BEP) for inter-
mediate risk germ cell cancer showed 12 % superior 3-year 
progression-free survival with T-BEP, when limited to eli-
gible patients (De Wit et al. 2012). The prospective study of 
TIP in the first-line setting for patients with intermediate- 
or poor-risk disease is now ongoing at MKSCC (Voss and 
Feldman 2011).
Finally, in the present study, we reviewed the medical 
records with special attention to toxicities during 116 cycles 
of TIP for 43 patients. To our knowledge, this is the larg-
est report on a toxicity profile of TIP in Japanese patients. 
Toxicities consisted mainly of myelosuppression, which is 
in line with previous studies. Most of the patients devel-
oped grade 3 or grade 4 leukocytopenia; subsequently, 23 
patients (53 %) suffered from febrile neutropenia, but all of 
them were manageable with empirical broad-spectrum anti-
biotics. Kondagunta et al. reported that 48 % of 46 patients 
developed neutropenic fever during TIP using a higher 
paclitaxel dose of 250 mg/m2 (Kondagunta et al. 2005). In 
the present study, five patients with relapsed or refractory 
disease received TIP as third-line or later chemotherapy. In 
consolidation chemotherapy, TIP was subsequently started 
after initial induction chemotherapy. The situations were 
different from MKSCC series, where all patients received 
TIP as second-line chemotherapy after continuous CR to 
prior CDDP-based regimens. To avoid serious complica-
tion, we fixed the dose of paclitaxel at 175 mg/m2; never-
theless, a half of patients experienced neutropenic fever. 
This might be due to the intensiveness of pretreatment in 
our patients, but there is a possibility that myelosuppres-
sion is more severe in Japanese patients. Besides myelo-
suppression, sensory neuropathy was frequently seen, and 
one patient experienced grade 3 neurotoxicity. Kondagunta 
et al. also reported that 4 % of patients developed grade 3 
neurotoxicity. In our series, no other non-hematological 
toxicities over grade 3 were observed. These observations 
suggest that TIP with paclitaxel at a higher dose is possible 
in Japanese patients. Because dose-finding study for pacli-
taxel in TIP regimen was not performed, we are panning 
the study using 210 mg/m2 of paclitaxel, which is the high-
est dose approved in Japan.
In conclusion, TIP was effective salvage chemother-
apy for relapsed patients with favorable risk features and 
selected CDDP-refractory patients. Results of TIP as con-
solidation for patients with an unfavorable response to 
the initial chemotherapy are also encouraging. Toxicities 
of TIP in these situations were manageable in most of the 
patients.
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